Wednesday, March 26, 2025 PA7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma trial has permanently closed. Primary PublicationRenouf DJ, Loree JM, Knox JJ, Topham JT, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko YJ, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Schaeffer DF, Gill S, Tu D, O'Callaghan CJ The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma :13(1):50202022 This study looked at a combination of durvalumab and tremelimumab when combined compared to either drug alone and while the combination has been studied in a few people, it is not clear if it can offer better results than standard treatment.Clinicaltrials.gov Results ReportingNCT02879318: Study results have been provided by the lead group to www.clinicaltrials.gov
